Pluri Inc. (NASDAQ:PLUR) Short Interest Update

Pluri Inc. (NASDAQ:PLUR) was the recipient of a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 18,100 shares, a drop of 29.8% from the February 28th total of 25,800 shares. Based on an average daily trading volume, of 11,100 shares, the days-to-cover ratio is presently 1.6 days. Currently, 0.5% of the shares of the company are short sold.

Pluri Stock Performance

Shares of NASDAQ:PLUR traded up $0.03 during mid-day trading on Friday, reaching $4.39. 6,479 shares of the company traded hands, compared to its average volume of 17,331. The company’s 50 day moving average price is $4.47 and its 200-day moving average price is $4.77. The firm has a market cap of $30.72 million, a PE ratio of -0.78 and a beta of 1.76. Pluri has a 52 week low of $4.07 and a 52 week high of $6.60. The company has a debt-to-equity ratio of 4.44, a current ratio of 5.04 and a quick ratio of 5.04.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.53) earnings per share for the quarter. Pluri had a negative return on equity of 2,778.13% and a negative net margin of 3,551.49%.

Institutional Investors Weigh In On Pluri

A hedge fund recently raised its stake in Pluri stock. Renaissance Technologies LLC increased its holdings in shares of Pluri Inc. (NASDAQ:PLUR) by 38.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,025 shares of the company’s stock after purchasing an additional 9,400 shares during the quarter. Renaissance Technologies LLC owned approximately 0.61% of Pluri worth $145,000 at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors.

Pluri Company Profile

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.